Not registered yet? Get a free account.
Sign UpYou're about to leave our website and go to an external link. Are you sure?
The company is a biopharmaceutical company, develops, manufactures, and sells biopharmaceuticals for diabetes, cancer, and autoimmune conditions.
Biocon Limited, is a listed public company incorporated on 29 November, 1978. It is classified as a public limited company and is located in Bangalore, Karnataka. It's authorized share capital is INR 625.00 cr and the total paid-up capital is INR 600.30 cr.
Read more
This action will use 1 of your credits. Are you sure you want to go ahead?
** All rupee values in INR crores. Based on March 2023 numbers.
* GST not included
** Reports & MCA filings will be based on the latest available financials.
State | Type | Address |
---|
Read more
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|
Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Networth | |||||
Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|
Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|
Sales + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Sales growth % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Expenses + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Cost of goods | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Employee cost | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other costs | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Operating profit + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Operating margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other income | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Interest | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Depreciation | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Exceptional items | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Profit before tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Profit - disc. ops | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Net margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|
Solvency + | |||||
Total Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Net Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Total Debt/Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Total Assets/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Liquidity + | |||||
Current Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Quick Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Interest Coverage | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Performance | |||||
Gross Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Operating Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Net Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Return + | |||||
Return on Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Pre-tax ROCE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Return on Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Pre-tax ROIC | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Efficiency + | |||||
Days Payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Days Inventory | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Days Receivable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Fixed Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Total Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Working Capital | |||||
Cash Conversion Cycle | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Working Capital Days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Vistra (ITCL) India Limited
No. of Loans: 1
Total Amount : 1,070.0 cr
Catalyst Trusteeship Limited
No. of Loans: 1
Total Amount : 500.0 cr
HDFC Bank Limited
No. of Loans: 1
Total Amount : 197.5 cr
DEPARTMENT OF BIOTECHNOLOGY
No. of Loans: 1
Total Amount : 5.7 cr
Department of Biotechnology
No. of Loans: 1
Total Amount : 4.4 cr
Designation | Name | DIN/PAN | Tenure |
---|---|---|---|
Director | Naina Lal Kidwai | 00017806 | 3 years |
Director | Bobby Kanubhai Parikh | 00019437 | 6 years |
Director | Ravi Rasendra Mazumdar
Shareholder
|
00109213 | 24 years |
Director | Kiran Mazumdar Shaw
Shareholder
|
00347229 | 15 years |
Director | Rekha Mehrotra Menon | 02768316 | 1 years |
Kmp | Siddharth Mittal | <HIDDEN> | 5 years |
Managing Director | Siddharth Mittal
Shareholder
|
03230757 | 5 years |
Director | Atul Dhawan | 07373372 | 0 years |
Director | Nicholas Robert Haggar | 08518863 | 1 years |
Director | Eric Vivek Mazumdar
Shareholder
|
09381549 | 3 years |
CS | Mayank Verma | <HIDDEN> | 5 years |
Kmp | Mukesh Katapadi Kamath | <HIDDEN> | 0 years |
Name | Status | Paid up Capital | Common Directors | Address |
---|---|---|---|---|
NAYARA ENERGY LIMITED |
Active
|
1,490.6 Cr | 1 | Gujarat |
ROTHSCHILD & CO INDIA PRIVATE LIMITED |
Active
|
13.5 Cr | 1 | Maharashtra |
UPL LIMITED |
Active
|
150.1 Cr | 1 | Gujarat |
GLAND PHARMA LTD |
Active
|
16.5 Cr | 1 | Telangana |
BMR BUSINESS SOLUTIONS PRIVATE LIMITED |
Active
|
8.5 L | 1 | Maharashtra |
TAXAND ADVISORS PRIVATE LIMITED |
Strike Off
|
1.0 L | 1 | Delhi |
BMR GLOBAL SERVICES PRIVATE LIMITED |
Active
|
1.0 L | 1 | Delhi |
INDOSTAR CAPITAL FINANCE LIMITED |
Active
|
136.1 Cr | 1 | Maharashtra |
AVAANA CAPITAL ADVISORS LLP |
Active
|
13,333.0 | 1 | Maharashtra |
INFOSYS LIMITED |
Active
|
2,076.1 Cr | 1 | Karnataka |
BIOCON BIOLOGICS LIMITED |
Active
|
1,758.3 Cr | 3 | Karnataka |
RELIANCE PETROLEUM LIMITED |
Amalgamated
|
4,500.0 Cr | 1 | Gujarat |
CLINIGENE INTERNATIONAL LIMITED |
Amalgamated
|
5.0 L | 2 | Karnataka |
GLENLOCH PROPERTIES LLP |
Active
|
1.0 L | 2 | Karnataka |
BIOCON BIOPHARMACEUTICALS LIMITED |
Amalgamated
|
17.6 Cr | 1 | Karnataka |
CSEP RESEARCH FOUNDATION |
Active
|
1.0 L | 1 | Delhi |
IMMUNEEL THERAPEUTICS PRIVATE LIMITED |
Active
|
4.6 L | 1 | Karnataka |
NARAYANA VAISHNO DEVI SPECIALTY HOSPITALS PRIVATE LIMITED |
Active
|
1.0 Cr | 1 | Karnataka |
BIOCON RESEARCH LIMITED |
Active
|
5.0 L | 1 | Karnataka |
BIOCON BIOSPHERE LIMITED |
Active
|
288.6 Cr | 3 | Karnataka |
SCIENCE GALLERY BENGALURU |
Active
|
0.0 | 1 | Karnataka |
BIOFUSION THERAPEUTICS LIMITED |
Active
|
5.0 L | 2 | Karnataka |
MAZUMDAR SHAW MEDICAL FOUNDATION |
Active
|
1.0 L | 1 | Karnataka |
NARAYANA HRUDAYALAYA LIMITED |
Active
|
204.4 Cr | 1 | Karnataka |
BIOCON PHARMA LIMITED |
Active
|
887.1 Cr | 3 | Karnataka |
BIOCON ACADEMY |
Active
|
5.0 L | 2 | Karnataka |
TRENT LIMITED |
Active
|
35.5 Cr | 1 | Maharashtra |
SYNGENE INTERNATIONAL LIMITED |
Active
|
402.5 Cr | 1 | Karnataka |
ACCENTURE SERVICES PRIVATE LIMITED |
Amalgamated
|
3.0 Cr | 1 | Maharashtra |
INVEST INDIA |
Active
|
1.0 Cr | 1 | Delhi |
COREOBJECTS INDIA PRIVATE LIMITED |
Amalgamated
|
58.0 L | 1 | Karnataka |
JOPASANA SOFTWARE & SYSTEMS PRIVATE LIMI TED |
Amalgamated
|
1.0 Cr | 1 | Karnataka |
DELOITTE FOUNDATION |
Active
|
20,000.0 | 1 | Maharashtra |
MAKING AN IMPACT THAT MATTERS FOUNDATION |
Active
|
20,000.0 | 1 | Maharashtra |
DELOITTE SHARED SERVICES INDIA LLP |
Active
|
2.7 Cr | 1 | Maharashtra |
Name | State / Country | Incorporation Year | Paidup Capital |
---|---|---|---|
SYNGENE INTERNATIONAL LIMITED | Karnataka | 1993 | ₹ 402.5 Cr |
BIOCON ACADEMY | Karnataka | 2013 | ₹ 5.0 L |
BIOCON PHARMA LIMITED | Karnataka | 2014 | ₹ 887.1 Cr |
Biocon SA, | Switzerland | - | - |
Biocon Biologics Limited | India | - | - |
Biocon Biologics UK Limited | United Kingdom | - | - |
Biocon Biologics SDN BHD | Malaysia | - | - |
Biocon Pharma Inc | United States | - | - |
Biocon FZ LLC | United Arab Emirates | - | - |
Biocon Biologics Healthcare Malaysia SDN BHD | Malaysia | - | - |
Syngene USA Inc | United States | - | - |
Biocon Pharma UK Limited | United Kingdom | - | - |
Biocon Pharma Ireland Limited | Ireland | - | - |
Biocon Biologics Inc, USA | United States | - | - |
BIOCON BIOSPHERE LIMITED | Karnataka | 2019 | ₹ 288.6 Cr |
Biocon Biologics FZ LLC | United Arab Emirates | - | - |
Biocon Biologics Do Brasil Ltda | Brazil | - | - |
Biocon Pharma Malta Limited | Malta | - | - |
Biocon Pharma Malta I Limited | Malta | - | - |
BIOFUSION THERAPEUTICS LIMITED | Karnataka | 2021 | ₹ 5.0 L |
SYNGENE MANUFACTURING SOLUTIONS LIMITED | Karnataka | 2022 | ₹ 1.0 Cr |
SYNGENE SCIENTIFIC SOLUTIONS LIMITED | Karnataka | 2022 | ₹ 399.0 Cr |
Biocon Biologics Germany GmbH | Germany | - | - |
Biocon Biologics Canada Inc. | Canada | - | - |
Biosimilars Newco Limited | United Kingdom | - | - |
Biosimilar Collaborations Ireland Limited | Ireland | - | - |
BIOCON SA | Switzerland | - | - |
BIOCON BIOLOGICS LIMITED | India | - | - |
BIOCON BIOLOGICS UK LIMITED | United Kingdom | - | - |
BIOCON SDN BHD | Malaysia | - | - |
Biocon Biologics Inc | United States | - | - |
Biocon Biologics Germany GmbH, Germany | Germany | - | - |
Biocon Biologics Canada Inc, Canada | Canada | - | - |
Biosimilars NewCo Limited, UK | United Kingdom | - | - |
Biosimilar Collaborations Ireland limited, Ireland | Ireland | - | - |
The incorporation date of BIOCON LIMITED is 29 November, 1978
The authorized share capital of BIOCON LIMITED is INR ₹ 625.0 Cr.
The paid-up capital of BIOCON LIMITED is INR ₹ 600.3 Cr.
The registered address of BIOCON LIMITED is 20th KM, Hosur Road, Electronic City Bengaluru Bangalore Karnataka - 560100
The CIN number of BIOCON LIMITED is L24234KA1978PLC003417.